252 related articles for article (PubMed ID: 29089811)
1. Clinical utility of multigene profiling assays in early-stage breast cancer.
Chang MC; Souter LH; Kamel-Reid S; Rutherford M; Bedard P; Trudeau M; Hart J; Eisen A;
Curr Oncol; 2017 Oct; 24(5):e403-e422. PubMed ID: 29089811
[TBL] [Abstract][Full Text] [Related]
2. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.
Blanchette P; Sivajohanathan D; Bartlett J; Eisen A; Feilotter H; Pezo R; Turashvili G; Williams P
Curr Oncol; 2022 Apr; 29(4):2599-2615. PubMed ID: 35448187
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
5. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
[TBL] [Abstract][Full Text] [Related]
6. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*
Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310
[TBL] [Abstract][Full Text] [Related]
7. Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany.
Lux MP; Minartz C; Müller-Huesmann H; Sandor MF; Herrmann KH; Radeck-Knorre S; Neubauer AS
Cancer Treat Res Commun; 2022; 31():100519. PubMed ID: 35093682
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Genomic Assay in Node-Positive Early-Stage Breast Cancer.
Pauls M; Chia S
Curr Oncol; 2022 Jul; 29(7):5139-5149. PubMed ID: 35877267
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
Yang M; Rajan S; Issa AM
Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer.
Alvarado MD; Prasad C; Rothney M; Cherbavaz DB; Sing AP; Baehner FL; Svedman C; Markopoulos CJ
Adv Ther; 2015 Dec; 32(12):1237-47. PubMed ID: 26610383
[TBL] [Abstract][Full Text] [Related]
11. Multigene tests for breast cancer: the physician's perspective.
Cognetti F; Biganzoli L; De Placido S; Del Mastro L; Masetti R; Naso G; Pruneri G; Santini D; Tondini CA; Tinterri C; Tonini G; Barni S
Oncotarget; 2021 Apr; 12(9):936-947. PubMed ID: 33953847
[TBL] [Abstract][Full Text] [Related]
12. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
13. Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?
Markopoulos C; van de Velde C; Zarca D; Ozmen V; Masetti R
Eur J Surg Oncol; 2017 May; 43(5):909-920. PubMed ID: 27639633
[TBL] [Abstract][Full Text] [Related]
14. Impact of gene expression profiling tests on breast cancer outcomes.
Marchionni L; Wilson RF; Marinopoulos SS; Wolff AC; Parmigiani G; Bass EB; Goodman SN
Evid Rep Technol Assess (Full Rep); 2007 Dec; (160):1-105. PubMed ID: 18457476
[TBL] [Abstract][Full Text] [Related]
15. Predicting Chemotherapy Benefit across Different Races in Early-Stage Breast Cancer Patients Using the Oncotype DX Score.
Shaw VR; Amos CI; Cheng C
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370827
[TBL] [Abstract][Full Text] [Related]
16. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
Lux MP; Nabieva N; Hildebrandt T; Rebscher H; Kümmel S; Blohmer JU; Schrauder MG
Breast; 2018 Feb; 37():89-98. PubMed ID: 29128582
[TBL] [Abstract][Full Text] [Related]
17. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
Henry NL; Somerfield MR; Abramson VG; Ismaila N; Allison KH; Anders CK; Chingos DT; Eisen A; Ferrari BL; Openshaw TH; Spears PA; Vikas P; Stearns V
J Clin Oncol; 2019 Aug; 37(22):1965-1977. PubMed ID: 31206315
[TBL] [Abstract][Full Text] [Related]
18. Genomic Signatures in Luminal Breast Cancer.
Puppe J; Seifert T; Eichler C; Pilch H; Mallmann P; Malter W
Breast Care (Basel); 2020 Aug; 15(4):355-365. PubMed ID: 32982645
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
